国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2010年
12期
1459-1462
,共4页
氟喹诺酮%联合用药%金黄色葡萄球菌%防突变浓度
氟喹諾酮%聯閤用藥%金黃色葡萄毬菌%防突變濃度
불규낙동%연합용약%금황색포도구균%방돌변농도
Fluoroquinolone%Combination therapy%Staphylococcus aureus%Mutant prevention concentration
目的 探讨山楂果胶寡糖与氟喹诺酮联合用药对金黄色葡萄球菌防耐药浓度的影响,为临床合理使用现有抗生素、防治细菌耐药产生提供理论依据.方法 采用标准琼脂二倍稀释法测定左氧氟沙星、环丙沙星对30株临床分离的金黄色葡萄球菌和金黄色葡萄球菌质控菌株ATCC25923的最低抑菌浓度(MIC),采用标准琼脂平板稀释法测定2种FQ药物对临床分离金黄色葡萄球菌的防突变浓度,计算单药和联合山楂果胶寡糖用药后该药的MPC50、MPC90.结果 左氧氟沙星单药对30株金黄色葡萄球菌的MPC范围在2～64mg/L,MPC90为32mg/L;联合山楂果胶寡糖后MPC范围为0.5～16 mg/L,MPC90降至8 mg/L.环丙沙星单药对30株金黄色葡萄球菌的MPC范围1～32mg/L,MPC90为16mg/L;联合山楂果胶寡糖后MPC范围0.25～8mg/L,MPC90降至4 mg/L,两组各项指标比较差异有显著性(P<0.05).结论 联合山楂果胶寡糖用药能降低环丙沙星、左氧氟沙星MPC,减少细菌耐药突变体的选择性富集扩增,防止抗菌药物耐药的产生.
目的 探討山楂果膠寡糖與氟喹諾酮聯閤用藥對金黃色葡萄毬菌防耐藥濃度的影響,為臨床閤理使用現有抗生素、防治細菌耐藥產生提供理論依據.方法 採用標準瓊脂二倍稀釋法測定左氧氟沙星、環丙沙星對30株臨床分離的金黃色葡萄毬菌和金黃色葡萄毬菌質控菌株ATCC25923的最低抑菌濃度(MIC),採用標準瓊脂平闆稀釋法測定2種FQ藥物對臨床分離金黃色葡萄毬菌的防突變濃度,計算單藥和聯閤山楂果膠寡糖用藥後該藥的MPC50、MPC90.結果 左氧氟沙星單藥對30株金黃色葡萄毬菌的MPC範圍在2～64mg/L,MPC90為32mg/L;聯閤山楂果膠寡糖後MPC範圍為0.5～16 mg/L,MPC90降至8 mg/L.環丙沙星單藥對30株金黃色葡萄毬菌的MPC範圍1～32mg/L,MPC90為16mg/L;聯閤山楂果膠寡糖後MPC範圍0.25～8mg/L,MPC90降至4 mg/L,兩組各項指標比較差異有顯著性(P<0.05).結論 聯閤山楂果膠寡糖用藥能降低環丙沙星、左氧氟沙星MPC,減少細菌耐藥突變體的選擇性富集擴增,防止抗菌藥物耐藥的產生.
목적 탐토산사과효과당여불규낙동연합용약대금황색포도구균방내약농도적영향,위림상합리사용현유항생소、방치세균내약산생제공이론의거.방법 채용표준경지이배희석법측정좌양불사성、배병사성대30주림상분리적금황색포도구균화금황색포도구균질공균주ATCC25923적최저억균농도(MIC),채용표준경지평판희석법측정2충FQ약물대림상분리금황색포도구균적방돌변농도,계산단약화연합산사과효과당용약후해약적MPC50、MPC90.결과 좌양불사성단약대30주금황색포도구균적MPC범위재2～64mg/L,MPC90위32mg/L;연합산사과효과당후MPC범위위0.5～16 mg/L,MPC90강지8 mg/L.배병사성단약대30주금황색포도구균적MPC범위1～32mg/L,MPC90위16mg/L;연합산사과효과당후MPC범위0.25～8mg/L,MPC90강지4 mg/L,량조각항지표비교차이유현저성(P<0.05).결론 연합산사과효과당용약능강저배병사성、좌양불사성MPC,감소세균내약돌변체적선택성부집확증,방지항균약물내약적산생.
Objective To provide supporting evidence for logical use of antibiotics by exploring the influence of combination therapy with Haw Pectin-derived pectic oligosaccharieds and fluoroquinolones on mutant prevention concentration of Staphylococcus aureus. Methods Minimal inhibitory concentrations (MIC) of levofloxacin and ciprofloxacin for staphylococcus aureus and quality control (ATCC25923) were determined by the standard two-fold agar dilution methods. MPC of fluoroquinolones for the strains were determined by spreading 1010cfu/ml coccus on agar plates containing single or two drugs at different concentrations. The values of MPC50 and MPC90 were calculated. Results For 30 clinical isolated ciprofloxacin and oxacillin-susceptible Staphylococcus aureus, MPC of levofloxacin alone was 2-64 mg/L and MPC90 was 32 mg/L and they reduced to 0.5-16mg/L and 8 mg/L on levofloxacin combined with pectic oligosaccharieds; MPC of of ciprofloxacin alone was 1-32 mg/L and MPC90 was 16 mg/L and they declined to 0.25-8 mg/L and 4 mg/L on ciprofloxacin plus pectic oligosaccharieds. Conculusions Combination with Haw Pectin-derived pectic oligosaccharieds can decrease MPCs of levofloxacin and ciprofloxacin, reduce the proliferation of drug-resistant mutants, and prevent the occurrence of drug resistance.
